CIK 0001490978 · Large accelerated filer
Schrodinger, Inc.
Sign in to watch- Ticker
- SDGR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 954284541
- Phone
- 503-299-1150
- Business address
- 1540 BROADWAY, 24TH FLOOR, NEW YORK, NY, 10036
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,781,663
- in 3 filings, $2.8M under 10b5-1 plans
Net −$2,781,663. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-18 | OBEROI ARUN Director | Grant or award | +5,997 | 17,247 | ||
| 2025-06-18 | OBEROI ARUN Director | Grant or award · Stock Option (right to buy) | +9,341 | 9,341 | ||
| 2025-06-18 | Friesner Richard Director | Grant or award | +5,997 | 521,697 | ||
| 2025-06-18 | Friesner Richard Director | Grant or award · Stock Option (right to buy) | +9,341 | 9,341 | ||
| 2025-05-29 | Aklian Mannix Vartan See Remarks | Grant or award | +14,063 | 14,063 | ||
| 2025-05-29 | Aklian Mannix Vartan See Remarks | Grant or award · Stock Option (right to buy) | +84,375 | 84,375 | ||
| 2025-05-21 | Jain Rachit EVP & CFO | Grant or award | +9,375 | 37,097 | ||
| 2025-05-21 | Jain Rachit EVP & CFO | Grant or award · Stock Option (right to buy) | +18,750 | 18,750 | ||
| 2025-04-14 | Akinsanya Karen President of R&D, Therapeutics | Option exercise 10b5-1 | +13,378 | $3.22 | $43K | 29,003 |
| 2025-04-14 | Akinsanya Karen President of R&D, Therapeutics | Option exercise 10b5-1 | +3,345 | $2.92 | $10K | 32,348 |
| 2025-04-14 | Akinsanya Karen President of R&D, Therapeutics | Sale 10b5-1 | −8,378 | $25.11 | $210K | 23,970 |
| 2025-04-14 | Akinsanya Karen President of R&D, Therapeutics | Sale 10b5-1 | −5,000 | $25.11 | $126K | 18,970 |
| 2025-04-14 | Akinsanya Karen President of R&D, Therapeutics | Sale 10b5-1 | −3,345 | $25.00 | $84K | 15,625 |
| 2025-04-14 | Akinsanya Karen President of R&D, Therapeutics | Option exercise · Stock Option (right to buy) 10b5-1 | −13,378 | 0 | ||
| 2025-04-14 | Akinsanya Karen President of R&D, Therapeutics | Option exercise · Stock Option (right to buy) 10b5-1 | −3,345 | 0 | ||
| 2025-03-07 | van Kralingen Bridget A Director | Grant or award | +10,000 | 10,000 | ||
| 2025-03-07 | van Kralingen Bridget A Director | Grant or award · Stock Option (right to buy) | +17,050 | 17,050 | ||
| 2025-03-06 | Herman Jenny SVP & Controller | Sale 10b5-1 | −666 | $21.11 | $14K | 27,349 |
| 2025-03-03 | Porges Geoffrey Craig EVP & CFO | Grant or award | +12,500 | 18,185 | ||
| 2025-03-03 | Porges Geoffrey Craig EVP & CFO | Grant or award | +14,850 | 33,035 |
Page 6 of 11 · 214 trades